Organophosphate nerve agents inhibit the enzyme acetylcholinesterase (AChE), whichi si nvolved in nerve signal transduction, by forming covalent adducts with its catalytic serine residue. AChE adducts with soman and sarin nerve agents undergo dealkylation, ap rocessk nown as aging, within af ew minutes and af ew hours,r espectively.T his transformation is detrimental because it precludes reactivation of AChE with known oxime-baseda ntidotes. Here, we designed a b-aminoalcohol molecule for aged AChE reactivation, using am ultitiered computationala pproach. This approach includes highquality quantum mechanical/molecular mechanical calculations, providing reliable reactivation steps and energetics. The calculations suggestt hat the designed b-aminoalcoholc an selectively reactivate aged sarin-/soman-inhibited AChE. Furthermore, unlike existing antidotes, the designed b-aminoalcohol lacks ap ermanent charge, making it potentially active in the centraln ervous system. Them echanistic insights of this study can helpg uide the development of new AChE reactivators with improved access to the centraln ervous system.
Introduction
Nerve agents disrupt nerve signal transductionb yc ovalently inhibiting acetylcholinesterase (AChE), an enzyme that breaks up the neurotransmitter acetylcholine in neural and neuromuscularj unctions. Unless treated promptly with an antidote that includes cholinergicr eceptor antagonists (e. g.,a tropine), inhibitorso fa cetylcholine release( e. g., diazepam), and oximebased AChE reactivators (e. g., 2-pralidoxime [2-PAM]; Figure 1) , [1] the developing cholinergicc rises can cause neurological damage and muscle functionloss, which ultimately lead to death.
The nerve agents soman ands arin present additional challenges because of their ability to undergo dealkylation after forming covalent adducts with the catalytic serine residue of AChE. Soman is of particular concern because the adduct it forms with AChE ages within af ew minutes, whereas the sarin adduct ages within af ew hours. Serendipitously,t he aged AChE adducts of soman and sarin are identical. [2] Unlike its precursors, the aged AChEa dduct is inert to existing oxime antidotes. [2] This property dramatically enhances the toxicity of soman and sarin. [1a] Although existing oxime antidotes can reactivate adducts of AChE and nerve agents within an arrow window of time between exposure and aging by dealkylation, their therapeutic effects are limited to neural and neuromuscular junctionso f the peripheraln ervous system. These antidotes are not as effective at neuralj unctions of the central nervouss ystem [1b, c] because their permanent positive charge, which mimics that of acetylcholine and aids in binding the actives ite of AChE, prevents them from crossing the blood-brain barriera nd thereby enabling therapeutic interventions in the central nervoussystem.
[1b]
One way to aid the permanently charged oxime antidotes in crossing the blood-brain barrier is to conjugate them with other small molecules that are actively transported across the barrier. [3] Alternatively,n ew antidotes could be developed withoutt he permanent charges ot hat they can passively cross cell membranes in the blood-brain barrier but then become Once aging occurs, existing antidotes no longerh elp reactivate AChE. In the absence of reactivators of the aged AChE adduct, restoring the concentration of activeA ChE to normall evelsb yde novo biosynthesis would require several days, which is inadequate for acute poisoning scenarios. [5] Therefore, finding aw ay to rapidlyr eactivate aged AChE in situ would significantly reduce the adversee ffects of nerve agent poisoning and help save human lives.
We are not aware of any antidote that selectively reactivates aged AChEb yi tself in either the peripheral or central nervous system. Unfortunately,n either oximes (aldoximes) nor amidoximes, which are most successful in reactivating AChE in the peripheraln ervous system before aging [1c, 4c, 6] , can reactivate the aged AChE adduct.
Because the aged AChE adduct is inert to existing oxime antidotes, as trategy has been proposed whereby the aged adduct is first alkylated and then subjected to reactivation with oximes. [7] However,f inding an ontoxic alkylating agent that selectively alkylates the aged AChE adduct under physiological conditions has provend ifficult. [7] Furthermore, using an alkylating agenta saprerequisite to the oxime reactivation may be problematic for pharmacokinetic reasons.
An ideal reactivation strategy,i no ur opinion, would be to use as mallm olecule that selectively reactivates aged AChE withoutt he need for pretreatment with alkylating agents. In addition, the ideal candidate molecule should cross the bloodbrain barrier, which is impenetrable to many permanently chargedm olecules. Finding an antidote capable of reactivating the aged AChE adduct and crossing the blood-brain barriert o deliver therapeutic effects inb oth the peripherala nd central nervoussystemswas the ultimate goal of the presentstudy.
Results and Discussion

Considerations for designing aged AChE reactivators
Severalf actors may preclude reactivation of the aged AChE adduct by oxime-baseda ntidotes. The main challenge is the permanent negative charge, created upon dealkylation,o nt he phosphonyl moiety of the nerve agents covalently attached to the catalytic seriner esidue. [2] This negative charged isables the catalytic machinery of AChE by forming as trong salt bridge with the positively charged catalytic histidine residue (H440) and, thereby prevents proton transfer from the histidine residue to the Og of the phosphonylated serine residue. Furthermore,t he negative charge on the phosphonyl moiety could electrostatically repel the negatively charged nucleophilic oxygen of the oxime antidotes.
Therefore, our design criteria excluded oxime nucleophiles. Instead, we pursued nucleophiles that are initially neutral but attain their full nucleophilic potential at or near the transition state for the Sn2 nucleophilic substitution reaction during reactivation of the aged AChE adduct.
Mechanistic insights from afunctionallysimilar enzyme
Recently,w er eported the results of am echanistic study of an unusuale nzyme, CapD,f rom the superfamily of N-terminal nucleophile (Ntn) hydrolases, which are functionally similart o AChE and serine proteases. [8] These enzymes are also inhibited by phosphonylation. [9] Their active sites, just like the active site of AChE, have an oxyanion hole that helps stabilize the tetrahedral intermediate formed during the Sn2 nucleophilic attack on their natural substrates. The principal difference among CapD,A ChE, and serine proteases ist hat instead of a canonical catalytic triad, such as Asp-His-Ser,t he CapD enzyme uses asingle N-terminal threonine residue.T he key moiety that enablest he catalytic function of the threonine residue is baminoalcohol.
Our earlier calculations demonstrated that the nucleophilic OgHg roup of the b-aminoalcohol moiety from the N-terminal catalytic threonine of CapD is deprotonated during the nucleophilic attack on its substrate, transferring its proton to the originally neutral N-terminal amino group. [10] Unlike oximes, the b-aminoalcoholn ucleophile is neutral at the beginning of the nucleophilic attack but developsanegative charge during an intramolecular proton transfer.T herefore, b-aminoalcohol satisfies our design criteria for having an uncharged nucleophile.
Incorporating mechanistic insights into the design of small molecule reactivators
The knowledge of the mechanism of CapD catalysis inspired us to design b-aminoalcoholm olecules that would bring the CapD-like catalytic machinery into the active site of aged AChE. Therefore, we derived an umber of small molecules by grafting the nucleophilic b-aminoalcohol fragment of the catalytic threonine residue of CapD onto the anchoring pyridine ring of the currently approved 2-PAM antidote (Figure 1 ) and several of its variants. The pyridine ring of 2-PAMh as ap ermanent positive charget hat should help anchor the grafted b-aminoalcohol in the active site of the aged AChE adduct. However, this permanent chargew ould preventt he molecule from crossingthe blood-brain barrier.
Testing the designedsmall molecule reactivators
To test whether the designed molecules could reactivate aged AChE, we used am ulti-tiered computational chemistry approach comprising 1)d ocking [11] of am olecule into the active site of the aged AChE adduct, 2)molecular dynamic simulations of the complex in solution, [12] and 3)h ybrid quantum mechanical/molecular mechanical (QM/MM) [13] reaction path [8, 10] calculations to assess the steps and energetics of aged AChE reactivation. Details of the approacha re provided in the Supporting Information.
The final stage of the multi-tiered simulations involved computationally intensiveQ M/MM simulations, using density functional theory for the QM portion of the simulations. This kind of QM/MM simulation allows high-fidelity studies of chemicalr eactions in enzymes and has been extensively used to study AChE catalysis, [14] phosphonylation, [15] aging, [16] and reactivation with oxime antidotes before aging. [16b, 17] To our best knowledge,t his work is the first such QM/MM study of reactivation of the aged AChE adduct. Furthermore, the QM region in our QM/MMs tudy is one of the largest reported to date (Figure 2) . The QM region included ac atalytic triad (E327, H440, and S200), an oxyanion hole (G118 and G119), ac holine anchoring residue (E199), an earbyY 121, five water molecules (w1-w5), and a b-aminoalcoholligand (molecule 1 or 2).
Aged AChE reactivation with molecule1
One of the best molecules identified that satisfied our design criteria was molecule 1 (Figure1) . This molecule has an asymmetricc arbon,w ith the S-enantiomer having the best configuration for reactivation of the aged AChE adduct. Despite the lack of an egative charge, the b-aminoalcoholn ucleophile graftedo nt he positively charged pyridinea nchor exhibited a reactivation barrier in excessof50kcal
The energy of the final product bound to reactivated AChE wasa lso very high (20 kcal . mol À1 ). The highly unfavorable reactivation with molecule 1 proceeded in one step. The absence of the expected trigonal bipyramidal metastable intermediate was most likely due to the requirement that it bear ad oubly negative charge and, thus, would not be sufficiently stabilized by the electrostatic environment of the aged AChE adduct. The water molecules in the active site were coupled to the reactivation andrearranged before the nucleophilic attack. Given the high barriera nd endothermicity of aged AChEr eactivationw ith molecule 1,t his reactionisunlikely to occur under physiological conditions. Analysiso ft he optimized reaction path for molecule 1 (not shown) demonstrated that the salt bridge between the catalytic H440 and the phosphonyl strongly resisted transfer of the proton from H440 to the Og oxygen of the phosphonylated S200, preventing reactivation of aged AChE. Developing the second negative chargeo nt he phosphonyl duringt he nucleophilic attack strengthened the salt bridge between H440 and the phosphonyl attached to S200. This observation suggested that the strength of the salt bridge would need to be reduced to achieve aged AChE reactivation.
Aged AChE reactivation with molecule 2
To reduce the strengtho ft he salt bridge between the catalytic H440 and the aged phosphonyl,w ei ncorporated an analogue of histidine into b-aminoalcohol molecule 2 (Figure 1) . Molecule 2 was derived from molecule 1 by swapping the Ca tom of the methyl group attached to the pyridine ring and the Na tom of the tertiary amine of the pyridine to create apositivelycharged NH 3 + group in the vicinity of both the choline anchoring E199 and the phosphonyl oxygenofthe covalently inhibited catalytic S200.
Swapping these atoms also moved the positive charge from the pyridine ring to its periphery in molecule 2. Unlike molecule 1,w hich has ap ermanent positive charge on the anchoring pyridine ring, molecule 2 is positivelyc harged because of ionization of one of its amino groups. Importantly, this charged group could becomen eutral under certain conditions that would enable molecule 2 to spontaneously cross the blood-brain barrier and therefore potentially act in the central nervous system. This property,w hich is required to deliver therapeutic effects to the central nervoussystem,makes molecule 2 our ideal candidate.
The positivelycharged amino group of molecule 2 formed a second salt bridge with the phosphonyl (Figure 2 A) , allowing the catalytic histidine residue to transfer its protont ot he oxygen of the phosphonylated serine residue. Optimization of the reaction paths for aged AChE reactivation with molecule 2 yielded areactivated AChE with significantly lower energy than did that with molecule 1. Reactivationw ith molecule 2 was slightly exothermic, by 1.1 kcal .T his attack successfully reactivated aged AChE (Figures 2C and 3) . Although the reaction path did not reveal a stable trigonal bipyramidal intermediate, it didh ave as houlder in the potential energy profile with the corresponding structure. In the final stages of the reaction, the five water molecules reorganized, providing additional stabilization to the reactivated AChE complex.
Importantly,t he reverse reaction, which could re-inhibit AChE, had ab arriero f25.3 kcal . mol
À1
;h ence, it should be substantially less likely than reactivation. This prediction suggestst hat aged phosphonylated molecule 2 would be unable to re-inhibit AChE.
The successo fmolecule 2 will depend on its ability to achieve the protonation state used for the reactivation reaction calculations upon binding aged AChE. Using simple pKa prediction tools [18] to estimate the pKas of the three ionizable aminog roups of molecule 2 in solution, we find that the bamine is protonatedf irst with ap Ka of 9.4, after which the two equivalent amines on the benzene ring are protonated second and third with pKas of 5.1 and 2.8, respectively.T herefore, under physiological conditions, the majority of molecules in a solution of molecule 2 will be singly protonated at the b-amine. However, proteins shift solution pKas by as much as 8p Ka units.
[19] Furthermore, these predictions do not take into account intramolecular interactions such as the one seen betweent he b-amine and the unprotonated amine of the benzene ring (Figure 2) .
The solutionp Ka of the b-aminog roup of molecule 2 can be altered significantly by using the lessons learnedf rom Ntn hydrolases.I nt he Supporting Information, we providet he results of several such pKa calculations for an umbero f derivatives of molecule 2. Furthermore, the methyl group of the benzene ring helps increase the pKas of the two amino groups on the ring (see SupportingInformation).
Using available experimentalk inetic data [20] and estimates of the free energy of activation in the two-stepc atalytic mechanism of AChE, [21] we estimated the pre-exponential factor for the acylation and deacylation steps of S200 to be on the order of 6 3 10 12 s À1 .G iven the predicted reactivation barrier of 17.0 kcal . mol À1 and assuming three orderso fm agnitude reduction of the pre-exponential factor while excluding unknowne ntropic contributionst ot he activation free energy,w e estimatet he reactionr ate for aged AChE reactivation with molecule2to be on the ordero f2 .6 3 
10
À3 s À1 at 300 K. Including the entropicc ontributions may significantly improve this estimate. This estimated reactionr ate would amount to a 50 %reactivation time of approximately 4minutes.
It remains to be seen whether molecule 2 will have a therapeutic effect against soman. To estimate the efficiency of aged AChE reactivation with molecule 2,o ne would need to know the binding constants for molecule 2 and for its aged phosphonylated product. Nevertheless,t he rough estimate of the aged AChE reactivation rate suggestst hat molecule 2 may achieve at herapeutic effect against nerve agent poisoning with soman.
In summary,a ged AChE reactivationw ith molecule 2 proceeded in two consecutive steps and was slightly exothermic (by 1.1 kcal . mol
À1
).
Conclusions
Our calculations predict that molecule 2,unlike its constitutional isomer molecule 1,m ay be able to reactivate aged AChE. The aged phosphonylated molecule 2 is not expected to re-inhibit AChE. To our best knowledge, molecule 2 is the first molecule that has been demonstrated, albeit computationally,t or eactivate aged AChE withoutt he need for alkylating agents. Our calculations assume that one of the two molecule 2 amino groups attached to the phenylr ing is protonated.T he protonated amino group bridges the choline anchoring negativelyc harged E199 and the negatively charged phosphonyl of the aged AChE adduct. This group is strategically placed and allows catalytic H440 to transfer its protont o phosphonylated S200. We wish to emphasize that in addition to the energetics that favor molecule 2 over molecule 1, molecule 2 differs from molecule 1 in one important regard. Specifically, molecule 2 does not have ap ermanent charge on its anchoring ring and can therefore cross the blood-brain barrier.Incontrast, molecule 1 has ap ermanent positive chargeo ni ts anchoring ring that would prevent it from passively crossing the blood-brain barrier. Therefore, molecule 2 is expected to act in both the peripherala nd central nervous systemsa nd is the ideal candidate for aged AChE reactivation.
Implications of the study for future work
The mechanistic insights gleaned from this study may enable redesign of existing oximes and afford new oximes capable of reactivating aged and nonaged AChE adducts in the central nervouss ystem.F urthermore, because b-aminoalcohols are predicted to successfully reactivate aged AChE, at ask considered to be impossible for existing oxime antidotes,w e anticipate that b-aminoalcohols may also be able to reactivate nonaged adducts of AChE and nerve agents. These predictions and molecular designstrategiesare made possible through our multi-tiered computational study of the steps and energetics of aged AChE reactivation.
